82 related articles for article (PubMed ID: 17919257)
1. Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.
Hoel AW; Conte MS
Cardiovasc Drug Rev; 2007; 25(3):221-34. PubMed ID: 17919257
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model.
Miyake T; Aoki M; Morishita R
Cardiovasc Res; 2008 Sep; 79(4):706-14. PubMed ID: 18515844
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH; Hafley G; Harrington RA; Peterson ED; Ferguson TB; Lorenz TJ; Goyal A; Gibson M; Mack MJ; Gennevois D; Califf RM; Kouchoukos NT;
JAMA; 2005 Nov; 294(19):2446-54. PubMed ID: 16287955
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.
Conte MS; Lorenz TJ; Bandyk DF; Clowes AW; Moneta GL; Seely BL
Vasc Endovascular Surg; 2005; 39(1):15-23. PubMed ID: 15696244
[TBL] [Abstract][Full Text] [Related]
5. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH; Ferguson TB; Joseph DM; Mack MJ; Wolf RK; Gibson CM; Gennevois D; Lorenz TJ; Harrington RA; Peterson ED; Lee KL; Califf RM; Kouchoukos NT;
Am Heart J; 2005 Oct; 150(4):643-9. PubMed ID: 16209958
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of carotis venous bypass graft disease by intraoperative nucleic acid-based therapy in rabbits.
Kusch B; Waldhans S; Sattler A; Wagner A; Hecker M; Moosdorf R; Vogt S
Thorac Cardiovasc Surg; 2006 Sep; 54(6):388-92. PubMed ID: 16967374
[TBL] [Abstract][Full Text] [Related]
7. Therapeutics of vein graft intimal hyperplasia: 100 years on.
Wallitt EJ; Jevon M; Hornick PI
Ann Thorac Surg; 2007 Jul; 84(1):317-23. PubMed ID: 17588453
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic possibilities for vein graft disease in the post-edifoligide era.
Cai X; Freedman NJ
Future Cardiol; 2006 Jul; 2(4):493-501. PubMed ID: 19804184
[TBL] [Abstract][Full Text] [Related]
9. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ
Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494
[TBL] [Abstract][Full Text] [Related]
10. E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.
Cho WH; Lee SO; Kim HT; Ahn JD; Lee IK
Transplant Proc; 2005; 37(1):77-9. PubMed ID: 15808553
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral activin A expression prevents vein graft intimal hyperplasia in a rat model.
Kloppenburg GT; Grauls GE; Bruggeman CA; Stassen FR
Interact Cardiovasc Thorac Surg; 2009 Jan; 8(1):31-4. PubMed ID: 18854336
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of edifoligide.
Parolari A; Alamanni F; Tremoli E; Biglioli P
JAMA; 2006 Apr; 295(13):1513; author reply 1514-5. PubMed ID: 16595751
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of edifoligide.
Desai ND; Fremes SE
JAMA; 2006 Apr; 295(13):1514; author reply 1514-5. PubMed ID: 16595752
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of edifoligide.
Lau GT; Kritharides L
JAMA; 2006 Apr; 295(13):1513-4; author reply 1514-5. PubMed ID: 16595750
[No Abstract] [Full Text] [Related]
15. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease.
Ehsan A; Mann MJ; Dell'Acqua G; Tamura K; Braun-Dullaeus R; Dzau VJ
Circulation; 2002 Apr; 105(14):1686-92. PubMed ID: 11940548
[TBL] [Abstract][Full Text] [Related]
16. Endothelin-1 and vein graft occlusion in patients undergoing bypass surgery.
Dashwood MR
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():78-87. PubMed ID: 19335750
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of intimal proliferation after vein grafting by chitosan nanoparticle with proliferation cell nuclear antigen-antisense oligo deoxy nucleotides].
Chen Z; Zhang H; Xia J
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Dec; 21(12):1348-54. PubMed ID: 18277682
[TBL] [Abstract][Full Text] [Related]
18. Molecular engineering of vein bypass grafts.
Conte MS
J Vasc Surg; 2007 Jun; 45 Suppl A():A74-81. PubMed ID: 17544027
[TBL] [Abstract][Full Text] [Related]
19. YSK2821, a newly synthesized indoledione derivative, inhibits cell proliferation and cell cycle progression via the cell cycle-related proteins by regulating phosphatidylinositol-3 kinase cascade in vascular smooth muscle cells.
Seo JM; Kim TJ; Jin YR; Han HJ; Ryu CK; Sheen YY; Kim DW; Yun YP
Eur J Pharmacol; 2008 May; 586(1-3):74-81. PubMed ID: 18402936
[TBL] [Abstract][Full Text] [Related]
20. In vitro paclitaxel and radiation effects on the cell types responsible for vascular stenosis: a preliminary analysis.
Zhang J; Melhem M; Kassing W; Kelly B; Wang Y; Krishnamoorthy M; Heffelfinger S; Desai P; Roy-Chaudhury P
Blood Purif; 2007; 25(2):155-60. PubMed ID: 17179736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
